BETA DRUGS LIMITED
BETA · General/Diversified · NSE
₹1,523
Current Market Price
Fair Value (DCF)
₹892
Discount to FV
-41.4%
Updated just now
YieldIQ Score
47/100
Piotroski F-Score
5/9
Economic Moat
Moderate
Confidence
46%
ROE
16.9%
Debt/Equity
0.60
WACC
11.1%
Market Cap
₹1,537 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
22.1%
Return on capital employed
EV / EBITDA
16.2×
Enterprise multiple
Debt / EBITDA
1.7×
Leverage vs earnings
Interest Coverage
9.5×
EBIT covers interest
Current Ratio
3.22×
Short-term liquidity
Asset Turnover
0.88×
Revenue per ₹ of assets
Revenue CAGR (3Y)
19.2%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,522.9
Bear case
Discount -183.5%
Base case
Discount -70.6%
Bull case
Discount -35.9%
Ratio Trends
BETA · last 5 annual periods
ROE
16.9%
ROCE
22.1%
Operating Margin
—
Debt / Equity
0.60×
PE
—
EV / EBITDA
—
Historical Financials
BETA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 yfinance | 2023 yfinance | 2024 yfinance | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹184 Cr | ₹227 Cr | ₹296 Cr | ₹362 Cr | ₹385 Cr | +20.3% |
| EBITDA | ₹43.3 Cr | ₹53.7 Cr | ₹61.2 Cr | ₹76.5 Cr | ₹86.9 Cr | +19.0% |
| EBIT | ₹36.1 Cr | ₹43.3 Cr | ₹51.4 Cr | ₹63.7 Cr | — | +15.3% |
| PAT | ₹24.8 Cr | ₹30.7 Cr | ₹36.4 Cr | ₹42.4 Cr | ₹41.5 Cr | +13.7% |
| EPS (diluted) | ₹24.59 | ₹30.43 | ₹37.90 | ₹42.02 | — | +14.3% |
| CFO | ₹29.6 Cr | ₹23.4 Cr | ₹30.9 Cr | ₹36.2 Cr | ₹37.3 Cr | +5.9% |
| CapEx | ₹-19.4 Cr | ₹-18.2 Cr | ₹-11.6 Cr | ₹-36.9 Cr | ₹-53.5 Cr | — |
| FCF | ₹10.2 Cr | ₹5.2 Cr | ₹19.3 Cr | ₹-0.7 Cr | ₹-16.2 Cr | — |
| Total Assets | ₹158 Cr | ₹198 Cr | ₹254 Cr | ₹436 Cr | ₹496 Cr | +33.1% |
| Total Debt | ₹20.6 Cr | ₹20.3 Cr | ₹14.7 Cr | ₹138 Cr | ₹148 Cr | +63.7% |
| Shareholders' Equity | ₹92.3 Cr | ₹123 Cr | ₹157 Cr | ₹197 Cr | ₹245 Cr | +27.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
BETA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
SYNCOMF SYNCOMF | — | — | Pending | 14.4% | — |
JAGSNPHARM JAGSNPHARM | — | — | Pending | 15.6% | 28.7× |
INDSWFTLAB INDSWFTLAB | — | — | Pending | 21.4% | — |
 AMRUTANJAN AMRUTANJAN | — | — | Pending | 15.6% | 24.6× |
 LINCOLN LINCOLN | — | — | Pending | 12.3% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for BETA in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. BETA DRUGS LIMITED (BETA.NS) trades at 1522.90 vs a model fair value of 892.47, a gap of -41.4%. Piotroski F-score: 5/9. Moat label: Mode...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of BETA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for BETA →
Compare
Head-to-head with peers
Compare BETA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse BETANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.